GNCA - ジェノシア・バイオサイエンシズ (Genocea Biosciences Inc.) ジェノシア・バイオサイエンシズ

 GNCAのチャート


 GNCAの企業情報

symbol GNCA
会社名 Genocea Biosciences Inc (ジェノシア・バイオサイエンシズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ジェノセア・バイオサイエンス(Genocea Biosciences Inc.)はT細胞免疫力を利用してワクチンと免疫療法を開発する。同社はその発見プラットフォームであるAnTigen Lead Acquisition System(ATLAS)を使用して、一部はT細胞(または細胞)免疫反応によって作用するワクチンおよび免疫療法を設計する。同社は、第III相臨床開発における1つの製品候補であり、性器ヘルペスの治療のための免疫療法であるGEN-003を有する。また、パーソナライズされた癌ワクチン(GEN-009)に焦点を合わせた前臨床免疫腫瘍学プログラムを有する。そのGEN-009プログラムは、ATLASを利用して、個体の腫瘍に関連する患者新生抗原、または各患者に固有の新たに形成された抗原を同定する。   ジェノシア・バイオサイエンシズは、米国のバイオ医薬品企業。ATLASプラットフォ―ム技術を用いて新型ワクチンの開発に従事。単純ヘルペスウイルス2型(HSV-2)の治療薬や、肺炎球菌の感染予防用ワクチンの製品候補の開発を手掛ける。またクラミジア予防プログラム、HSV-2予防プログラム、マラリア予防プログラムなど開発プログラムを手掛ける。   Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.
本社所在地 100 Acorn Park Drive Cambridge MA 02140 USA
代表者氏名 Katrine S. Bosley Katrine S. Bosley
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 617-876-8191
設立年月日 38930
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 52人
url www.genocea.com
nasdaq_url https://www.nasdaq.com/symbol/gnca
adr_tso
EBITDA EBITDA(百万ドル) -43.25400
終値(lastsale) 0.8
時価総額(marketcap) 69300780
時価総額 時価総額(百万ドル) 62.71721
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 33.67221
当期純利益 当期純利益(百万ドル) -47.92800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Genocea Biosciences Inc revenues was not reported. Net loss decreased 30% to $20.3M. Lower net loss reflects Research and Development - Bal Val decrease of 40% to $12.3M (expense) General and administrative decrease of 35% to $936K (expense) stock based-Research and development decrease of 59% to $300K (expense).

 GNCAのテクニカル分析


 GNCAのニュース

   Silicon Therapeutics Appoints Pamela Carroll, Ph.D. as Chief Business Officer  2020/08/04 20:00:00 Business Wire
BOSTON--(BUSINESS WIRE)--Silicon Therapeutics (SiTX) announced today that Pamela Carroll, Ph.D. has been appointed Chief Business Officer to lead corporate strategy and business development. Dr. Carroll joins Silicon Therapeutics after more than 20 years in senior research and leadership positions at Johnson & Johnson, Roche, the Dana Farber Cancer Institute, and most recently at Genocea Biosciences, where she served as Senior Vice President of Immuno-oncology. “Silicon Therapeutics is at t
   The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings  2020/07/26 13:54:59 Benzinga
Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks. Although there were promising updates from some coronavirus vaccine makers, negative headlines plagued Novavax, Inc. (NASDAQ: NVAX ) and Moderna Inc (NASDAQ: MRNA ), sending their stocks lower by 4.7% and 23%, respectively, for the week. The week saw the listing of 4 biopharma companies on the Nasdaq, which raised a combined $772.9 million. Here are the key catalysts for the unfolding week. Conferences: Alzheimer's Association International Conference, or AAIC, to be held virtually: July 27-31 PDUFA Dates The FDA is set to rule on Ultragenyx Pharmaceutical Inc's (NASDAQ: RARE ) NDA for UX007, its investigational drug for long-chain fatty acid oxidation disorders. (Friday) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) has a PDUFA action date, with the FDA due to announce its verdict on the company's sNDA for Epidiolex for the treatment of seizures associated with tuberous sclerosis complex.
   Genocea Biosciences, Inc. (GNCA) Shares March Higher, Can It Continue?  2020/04/23 15:44:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in Genocea Biosciences, Inc. (GNCA).
   The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection  2020/03/19 11:37:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ: BMRA )( announced commencement of international shipment of rapid COVID-19 test) BioNTech SE – ADR (NASDAQ: BNTX ) Imara Inc (NASDAQ: IMRA ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 18) 89bio Inc (NASDAQ: ETNB ) AC Immune SA (NASDAQ: ACIU ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) ADMA Biologics Inc (NASDAQ: ADMA ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agenus Inc (NASDAQ: AGEN ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Aikido Pharma Inc (NASDAQ: AIKI ) Akorn, Inc. (NASDAQ: AKRX ) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Alterity Therapeutics Ltd (NASDAQ: ATHE ) AMAG Pharmaceuticals, Inc.
   The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy  2020/02/27 12:35:07 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate Therapeutics Inc (NASDAQ: FATE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Inspire Medical Systems Inc (NYSE: INSP ) (reacted to fourth-quarter results) Mersana Therapeutics Inc (NASDAQ: MRSN ) Moderna Inc (NASDAQ: MRNA ) Nevro Corp (NYSE: NVRO ) (announced fourth-quarter results) Oyster Point Pharma Inc (NASDAQ: OYST ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Revolution Medicines Inc (NASDAQ: RVMD ) Vir Biotechnology Inc (NASDAQ: VIR ) (announced a collaboration with WuXi Biologics for the development of antibodies to treat COVID-19) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Auris Medical Holding Ltd (NASDAQ: EARS )(announced publication of results of a study showing anti-epileptic and anti-convulsive activity of betahistine in a mouse model) Blueprint Medicines Corp (NASDAQ: BPMC ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Curis, Inc. (NASDAQ: CRIS ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galectin Therapeutics Inc.
   Genocea Biosciences, Inc. (GNCA) Shares March Higher, Can It Continue?  2020/04/23 15:44:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in Genocea Biosciences, Inc. (GNCA).
   The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection  2020/03/19 11:37:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ: BMRA )( announced commencement of international shipment of rapid COVID-19 test) BioNTech SE – ADR (NASDAQ: BNTX ) Imara Inc (NASDAQ: IMRA ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 18) 89bio Inc (NASDAQ: ETNB ) AC Immune SA (NASDAQ: ACIU ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) ADMA Biologics Inc (NASDAQ: ADMA ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agenus Inc (NASDAQ: AGEN ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Aikido Pharma Inc (NASDAQ: AIKI ) Akorn, Inc. (NASDAQ: AKRX ) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Alterity Therapeutics Ltd (NASDAQ: ATHE ) AMAG Pharmaceuticals, Inc.
   The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy  2020/02/27 12:35:07 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate Therapeutics Inc (NASDAQ: FATE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Inspire Medical Systems Inc (NYSE: INSP ) (reacted to fourth-quarter results) Mersana Therapeutics Inc (NASDAQ: MRSN ) Moderna Inc (NASDAQ: MRNA ) Nevro Corp (NYSE: NVRO ) (announced fourth-quarter results) Oyster Point Pharma Inc (NASDAQ: OYST ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Revolution Medicines Inc (NASDAQ: RVMD ) Vir Biotechnology Inc (NASDAQ: VIR ) (announced a collaboration with WuXi Biologics for the development of antibodies to treat COVID-19) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Auris Medical Holding Ltd (NASDAQ: EARS )(announced publication of results of a study showing anti-epileptic and anti-convulsive activity of betahistine in a mouse model) Blueprint Medicines Corp (NASDAQ: BPMC ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Curis, Inc. (NASDAQ: CRIS ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galectin Therapeutics Inc.
   Precision Medicine Market: Industry Analysis and Detailed Profiles of Neon Therapeutics, Moderna, Inc, Merck & Co., Inc, Bayer AG, PERSONALIS INC, GENOCEA BIOSCIENCES, INC | Data Bridge Market Research  2019/12/06 10:11:00 PR Newswire
SAN FRANCISCO, Dec. 6, 2019 /PRNewswire/ -- The perfect way to anticipate what future holds is to understand the trend today and hence Global Precision Medicine Market report has been structured by chewing over numerous fragments of the present and upcoming market scenario. The report…
   Genocea Biosciences Enters Oversold Territory  2019/11/14 13:30:00 Zacks Investment Research
Genocea Biosciences has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
   Genocea Biosciences, Inc. (GNCA) Shares March Higher, Can It Continue?  2020/04/23 15:44:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in Genocea Biosciences, Inc. (GNCA).
   The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection  2020/03/19 11:37:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ: BMRA )( announced commencement of international shipment of rapid COVID-19 test) BioNTech SE – ADR (NASDAQ: BNTX ) Imara Inc (NASDAQ: IMRA ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 18) 89bio Inc (NASDAQ: ETNB ) AC Immune SA (NASDAQ: ACIU ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) ADMA Biologics Inc (NASDAQ: ADMA ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agenus Inc (NASDAQ: AGEN ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Aikido Pharma Inc (NASDAQ: AIKI ) Akorn, Inc. (NASDAQ: AKRX ) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Alterity Therapeutics Ltd (NASDAQ: ATHE ) AMAG Pharmaceuticals, Inc.
   The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy  2020/02/27 12:35:07 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate Therapeutics Inc (NASDAQ: FATE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Inspire Medical Systems Inc (NYSE: INSP ) (reacted to fourth-quarter results) Mersana Therapeutics Inc (NASDAQ: MRSN ) Moderna Inc (NASDAQ: MRNA ) Nevro Corp (NYSE: NVRO ) (announced fourth-quarter results) Oyster Point Pharma Inc (NASDAQ: OYST ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Revolution Medicines Inc (NASDAQ: RVMD ) Vir Biotechnology Inc (NASDAQ: VIR ) (announced a collaboration with WuXi Biologics for the development of antibodies to treat COVID-19) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Auris Medical Holding Ltd (NASDAQ: EARS )(announced publication of results of a study showing anti-epileptic and anti-convulsive activity of betahistine in a mouse model) Blueprint Medicines Corp (NASDAQ: BPMC ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Curis, Inc. (NASDAQ: CRIS ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galectin Therapeutics Inc.
   Precision Medicine Market: Industry Analysis and Detailed Profiles of Neon Therapeutics, Moderna, Inc, Merck & Co., Inc, Bayer AG, PERSONALIS INC, GENOCEA BIOSCIENCES, INC | Data Bridge Market Research  2019/12/06 10:11:00 PR Newswire
SAN FRANCISCO, Dec. 6, 2019 /PRNewswire/ -- The perfect way to anticipate what future holds is to understand the trend today and hence Global Precision Medicine Market report has been structured by chewing over numerous fragments of the present and upcoming market scenario. The report…
   Genocea Biosciences Enters Oversold Territory  2019/11/14 13:30:00 Zacks Investment Research
Genocea Biosciences has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ジェノシア・バイオサイエンシズ GNCA Genocea Biosciences Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)